Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal second quarter ended Sept. 30 came to 19 Indian paise per share, a gain of 43.2% from 13 paise per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.3 million rupees, an increase of 40.0% from 962,500 rupees in the prior-year period.
The normalized profit margin rose to 1.4% from 1.0% in the year-earlier period.
Total revenue grew year over year to 97.6 million rupees from 93.5 million rupees, and total operating expenses climbed from the prior-year period to 91.9 million rupees from 89.9 million rupees.
Reported net income increased 46.6% on an annual basis to 1.5 million rupees, or 21 paise per share, from 1.0 million rupees, or 14 paise per share.
As of Nov. 17, US$1 was equivalent to 61.80 Indian rupees.
